Heart failure & cardiomyopathiesRandomised controlled trial
Verinurad Plus Allopurinol for Heart Failure With Preserved Ejection Fraction
- Randomised controlled trial
- phase 2
- double-blind
- 59 centres in 12 countries
All patients received oral colchicine 0.5 to 0.6 mg daily for the first 12 weeks
Authors' conclusion
Results of this randomized clinical trial show that despite substantial SUA lowering, verinurad plus allopurinol did not result in a significant improvement in peak VO2 or symptoms compared with allopurinol monotherapy or placebo in HFpEF.
Study context
- Population
- Patients ≥40 years with heart failure with preserved ejection fraction (HFpEF) and serum uric acid (SUA) >6 mg/dLrandomised
- Participants
- 159 patients
- Comparison
- Verinurad plus allopurinol vs allopurinol monotherapy vs placebo
- Verinurad plus allopurinoln = 53
- Allopurinoln = 53
- Placebon = 53reference
- Primary endpoint
- Key end points: changes in peak VO2, KCCQ-TSS and SUA level
- Follow-up
- Baseline to week 32
Primary result
As reported in the abstract
Change in peak VO2 and KCCQ-TSS; SUA level · week 32
| Group | Value | Kansas City Cardiomyopathy Questionnaire total symptom score (KCCQ-TSS) change | SUA mean change |
|---|---|---|---|
| Verinurad plus allopurinol | change 0.27 (95% CI −0.56–1.10) mL/kg/min | 4.3 (95% CI, 0.3-8.3) | −59.6% (95% CI, −64.4% to −54.2%) |
| Allopurinol | change −0.17 (95% CI −1.03–0.69) mL/kg/min | 4.5 (95% CI, 0.3-8.6) | −37.6% (95% CI, −45.3% to −28.9%) |
| Placebo | change 0.37 (95% CI −0.45–1.19) mL/kg/min | 1.2 (95% CI, −3.0 to 5.3) | 0.8% (95% CI, −11.8% to 15.2%) |
- Verinurad plus allopurinol lowered SUA more than allopurinol or placebo
- P < 0.001
Further findings
Deaths or CV events
Deaths or CV events
- No adverse safety signals
Original publication
Verinurad Plus Allopurinol for Heart Failure With Preserved Ejection Fraction. JAMA Cardiol. Published 1 October 2024. doi:10.1001/jamacardio.2024.2435
Summarised from the published abstract; every number is checked against it